<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a randomized phase II study, patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with 10-30% blasts in the bone marrow and hematopoietic failure were treated with low-dose Ara C (2 x 10 mg/m2 subcutaneously (s.c.) days 1-14) and rhGM-CSF (fully glycosylated, Sandoz/Schering-Plough, 2 x 150 micrograms protein/day s.c.) given either following Ara C (days 15-21) or simultaneously (days 8-14) for 1-5 cycles </plain></SENT>
<SENT sid="1" pm="."><plain>108 patients with a median age of 65 years, range 17-80 years and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with an excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, n = 54), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> with transformation (RAEBt, n = 50) or with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, n = 4) were evaluable </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission was achieved in 15 cases (14%), 11 had a partial response (10%), and 16 a minor response (15%) </plain></SENT>
<SENT sid="3" pm="."><plain>Stable disease was reached in 35 cases (32%) </plain></SENT>
<SENT sid="4" pm="."><plain>There were 16 cases of toxic <z:hpo ids='HP_0011420'>death</z:hpo> (15%), progression occurred in 15 patients (14%) </plain></SENT>
<SENT sid="5" pm="."><plain>No differences existed between the two treatment arms with respect to response and duration of response </plain></SENT>
<SENT sid="6" pm="."><plain>Prognostic factors for poor response included the presence of cytogenetic abnormalities and a history of previous blood transfusions </plain></SENT>
<SENT sid="7" pm="."><plain>Major adverse events during treatment were <z:mp ids='MP_0001914'>hemorrhage</z:mp> (55%), <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (54%), and <z:hpo ids='HP_0001945'>fever</z:hpo> associated with GM-CSF administration (40%) </plain></SENT>
<SENT sid="8" pm="."><plain>The overall response rate ws 39%, median duration was 12.5 months from start of treatment which allowed responding patients to lead good quality life without further therapy </plain></SENT>
<SENT sid="9" pm="."><plain>The question whether the combination is indeed superior to LD-Ara C alone is not settled but will be evaluated in an ongoing clinical trial </plain></SENT>
</text></document>